NEW YORK (GenomeWeb) – The China Food and Drug Administration has approved next-generation sequencing-based products developed by BGI.

According to CFDA, it has approved BGISEQ-1000, BGISEQ-100, and diagnostic kits for fetal chromosomal aneuploidy that screen for trisomy 21, 18, and 13. The CFDA said the assays use semiconductor sequencing and joint probe anchor sequencing and will screen cell-free DNA in maternal plasma at 12 weeks or later gestation.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.

Sep
17
Sponsored by
SeraCare

Today’s challenging clinical next-generation sequencing applications require a rigorous, comprehensive quality control management program to ensure confidence in results.